FDA approves Syfovre as first treatment for geographic atrophy

USA: Pegcetacoplan injection (Syfovre) has received approval from the US Food and Drug Administration (FDA) as the first treatment for geographic atrophy (GA) secondary to age-related macular degeneration (AMD). 

Syfovre is the first and only FDA-approved treatment for geographic atrophy, a leading cause of blindness that impacts more than one million people in the U.S. and five million people worldwide.

Pegcetacoplan reduced GA lesion growth by 22% over 24 months versus sham injections, with reductions of as much as 30% with monthly intravitreal injections. 

“The approval of SYFOVRE is the most important event in retinal ophthalmology in more than a decade,” said Eleonora Lad, M.D., Ph.D., lead investigator for the OAKS study, director of ophthalmology clinical research, associate professor of ophthalmology, Duke University Medical Center. “Until now, there have been no approved therapies to offer people living with GA as their vision relentlessly declined. With SYFOVRE, we finally have a safe and effective GA treatment for this devastating disease, with increasing effects over time.”

“Today marks an extraordinary milestone for patients, the retina community, and Apellis. With its increasing effects over time and flexible dosing, we believe that SYFOVRE will make a meaningful difference in the lives of people with GA,” said Cedric Francois, M.D., Ph.D., co-founder and chief executive officer, Apellis. “GA is a complex disease that the field has spent decades trying to address, so we are humbled and proud to bring forward the first-ever treatment. Thank you to all who helped make this moment a reality.”

The approval of SYFOVRE is based on positive results from the Phase 3 OAKS and DERBY studies at 24 months across a broad and representative population of patients. SYFOVRE is approved for GA patients with or without subfoveal involvement and provides dosing flexibility for patients and physicians with a dosing regimen of every 25 to 60 days. In the OAKS and DERBY studies, SYFOVRE reduced the rate of GA lesion growth compared to sham and demonstrated increasing treatment effects over time, with the greatest benefit (up to 36% reduction in lesion growth with monthly treatment in DERBY) occurring between months 18-24.

“For the first time ever, we are celebrating the approval of a treatment for GA,” said Jeff Todd, president and chief executive officer, of Prevent Blindness. “This is a historic and hopeful day for all GA patients and their care partners, who have been waiting for treatment for this relentless form of vision loss.”

GA is an advanced form of AMD. It is a progressive and irreversible disease caused by the growth of lesions, which destroy the retinal cells responsible for vision. The vision loss caused by GA severely impairs independence and quality of life by making it difficult to participate in daily activities. On average, it takes only 2.5 years for GA lesions to start impacting the fovea, which is responsible for central vision.3

The safety profile of SYFOVRE is well-demonstrated following ~12,000 injections. The most common adverse reactions (≥ 5%) reported in patients receiving SYFOVRE were ocular discomfort, neovascular AMD, vitreous floaters, and conjunctival hemorrhage.

Apellis is committed to helping patients with treatment access and support. ApellisAssist® is a program designed to help SYFOVRE patients along their treatment journey by providing a system inclusive of insurance support, financial assistance for eligible patients, disease education, and ongoing product support. Patients and healthcare providers can call 1-888-273-5547 for more information.

SYFOVRE is expected to be available by the beginning of March through specialty distributors and specialty pharmacies nationwide. A marketing authorization application for SYFOVRE is under review by the European Medicines Agency with a decision expected in early 2024. In addition, a marketing application has been submitted to Health Canada.